Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel Targets
| Solid tumor program | Annual addressable metastatic US patients | Target and engager | Discovery > Lead optimisation > IND enabling | Status |
|---|---|---|---|---|
| BA211 Dual-indication* | > 10,000 HLA-A2+ | TC11 αCD3 TCE | DC Selection 2H25 IND 1H27 | |
| BA2168 Multi-indication* | > 60,000 HLA-A2+ | TC168 αCD3 TCE | DC Selection 1H26 IND 2H27 | |
| BA225 Multi-indication* | > 60,000 HLA-A2+ | TC25 Undisclosed | DC Selection 1H26 IND 2H27 | |
| Multiple | > 60,000 Pan-HLA+ | Undisclosed | Lead selection |
*High potential indications including MSS CRC, Gastric, Oesophageal (Sq./Ad), Lung (Sq/Ad), Melanoma, HNSCC, Bladder, Pancreatic
| Autoimmune program | Annual addressable metastatic US patients | Target and engager | Discovery > Lead optimisation > IND enabling | Status |
|---|---|---|---|---|
| BA301 Multi-indication | Autoimmune Not HLA-restricted | TC301 Undisclosed | Lead selection |
Other targets
| Solid tumor program | Annual addressable metastatic US patients | Target and engager | Discovery > Lead optimisation > IND enabling | Status |
|---|---|---|---|---|
| BA201 BA202 BA2401 | 20,000-40,000 | MAGE-A4/A8 PRAME A2 PRAME A24 | DC Selection 2026 |
